^
    12d
    PRAME Immunohistochemistry-Guided Slow Mohs Micrographic Surgery for the Treatment of Stage 0 to IIc Cutaneous Melanoma (clinicaltrials.gov)
    P=N/A, N=36, Suspended, University of California, Davis | Recruiting --> Suspended
    Trial suspension
    |
    PRAME (Preferentially Expressed Antigen In Melanoma)
    13d
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=360, Recruiting, Immatics US, Inc. | N=108 --> 360
    Enrollment change
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)
    14d
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=108, Recruiting, Immatics US, Inc.
    New P3 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)
    22d
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=360, Recruiting, Immatics US, Inc. | N=96 --> 360
    Enrollment change
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)
    28d
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=96, Recruiting, Immatics US, Inc.
    New P3 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)
    29d
    LuCa-MERIT-1: Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=320, Recruiting, BioNTech SE | N=156 --> 320
    Enrollment change • First-in-human
    |
    ALK (Anaplastic lymphoma kinase) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • RET rearrangement
    |
    Tagrisso (osimertinib) • carboplatin • paclitaxel • docetaxel • Libtayo (cemiplimab-rwlc) • gotistobart (BNT316) • BNT116
    2ms
    IMC-F106C-101: Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors (clinicaltrials.gov)
    P1/2, N=410, Active, not recruiting, Immunocore Ltd | Recruiting --> Active, not recruiting | N=727 --> 410 | Trial completion date: Aug 2026 --> Dec 2027 | Trial primary completion date: Feb 2026 --> Oct 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition • First-in-human
    |
    PRAME (Preferentially Expressed Antigen In Melanoma)
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Kimmtrak (tebentafusp-tebn) • brenetafusp (IMC-F106C)
    2ms
    TK-6302-01: A study testing a new treatment called TK-6302 for the first time in people with advanced cancers that have a genetic marker called HLA-A02:01 and a tumour protein called PRAME. (2025-521603-46-00)
    P1, N=24, Not yet recruiting, T-Knife GmbH
    New P1 trial
    3ms
    PRAME Immunohistochemistry-Guided Slow Mohs Micrographic Surgery for the Treatment of Stage 0 to IIc Cutaneous Melanoma (clinicaltrials.gov)
    P=N/A, N=36, Recruiting, University of California, Davis | Withheld --> Recruiting
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    PRAME (Preferentially Expressed Antigen In Melanoma)
    3ms
    Shared PRAME epitopes are T-cell targets in NUT carcinoma. (PubMed, J Immunother Cancer)
    PRAME is highly and frequently expressed in NUT carcinoma, and the most common oncoprotein causing NUT carcinoma, BRD4::NUTM1, contributes to these high PRAME levels. PRAME epitopes presented by HLA class I are a previously unrecognized therapeutic vulnerability for NUT carcinoma that warrants clinical trials testing PRAME-targeted immunotherapies in this neglected patient population.
    Journal • IO biomarker
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • NSD3 (Nuclear Receptor Binding SET Domain Protein 3) • PRAME (Preferentially Expressed Antigen In Melanoma) • BRD4 (Bromodomain Containing 4) • NUTM1 (NUT Midline Carcinoma Family Member 1) • BRD3 (Bromodomain Containing 3)
    |
    brenetafusp (IMC-F106C)
    5ms
    TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors (clinicaltrials.gov)
    P1, N=24, Recruiting, Neowise Biotechnology
    New P1 trial
    7ms
    TACTOPS: TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=37, Completed, Baylor College of Medicine | Trial completion date: May 2027 --> Jul 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date